Efficacy comparison of adjuvants in PcrV vaccine againstPseudomonas aeruginosapneumonia
出版年份 2017 全文链接
标题
Efficacy comparison of adjuvants in PcrV vaccine againstPseudomonas aeruginosapneumonia
作者
关键词
-
出版物
MICROBIOLOGY AND IMMUNOLOGY
Volume 61, Issue 2, Pages 64-74
出版商
Wiley
发表日期
2017-03-29
DOI
10.1111/1348-0421.12467
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- IV Immunoglobulin for Acute Lung Injury and Bacteremia in Pseudomonas aeruginosa Pneumonia*
- (2016) Hideya Katoh et al. CRITICAL CARE MEDICINE
- Protective effects of intravenous immunoglobulin and antimicrobial agents on acute pneumonia in leukopenic mice
- (2016) Masaru Shimizu et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Type III Secretion: Building and Operating a Remarkable Nanomachine
- (2016) Athina G. Portaliou et al. TRENDS IN BIOCHEMICAL SCIENCES
- Pseudomonas aeruginosarenews its virulence factors
- (2016) Philippe Huber et al. Environmental Microbiology Reports
- The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa
- (2016) Mao Kinoshita et al. Human Vaccines & Immunotherapeutics
- Cellular Effects of Pyocyanin, a Secreted Virulence Factor of Pseudomonas aeruginosa
- (2016) Susan Hall et al. Toxins
- On vaccine's adjuvants and autoimmunity: Current evidence and future perspectives
- (2015) Paolo Pellegrino et al. AUTOIMMUNITY REVIEWS
- Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies
- (2015) Mohamed E El Zowalaty et al. Future Microbiology
- Pseudomonas aeruginosa: Evolution of Antimicrobial Resistance and Implications for Therapy
- (2015) Kate McCarthy SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- Bacterial Type III Secretion Systems: Specialized Nanomachines for Protein Delivery into Target Cells
- (2014) Jorge E. Galán et al. Annual Review of Microbiology
- Immunomodulatory properties of the vaccine adjuvant alum
- (2014) Ewa Oleszycka et al. CURRENT OPINION IN IMMUNOLOGY
- Vaccines forPseudomonas aeruginosa: a long and winding road
- (2014) Gregory P Priebe et al. Expert Review of Vaccines
- Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update
- (2014) Jean-Louis Vincent Future Microbiology
- V-antigen homologs in pathogenic gram-negative bacteria
- (2014) Teiji Sawa et al. MICROBIOLOGY AND IMMUNOLOGY
- Protective Effect of DNA Vaccine Encoding Pseudomonas Exotoxin A and PcrV against Acute Pulmonary P. aeruginosa Infection
- (2014) Mingzi Jiang et al. PLoS One
- Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist
- (2014) K. Kobiyama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury
- (2014) Qin Wang et al. RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY
- Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa
- (2014) Teiji Sawa et al. Human Vaccines & Immunotherapeutics
- Vaccination against respiratoryPseudomonas aeruginosainfection
- (2014) Keith Grimwood et al. Human Vaccines & Immunotherapeutics
- Recent progress concerning CpG DNA and its use as a vaccine adjuvant
- (2013) Hidekazu Shirota et al. Expert Review of Vaccines
- Key roles of adjuvants in modern vaccines
- (2013) Steven G Reed et al. NATURE MEDICINE
- A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of aPseudomonas aeruginosahybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers
- (2013) Kerstin Westritschnig et al. Human Vaccines & Immunotherapeutics
- Mechanisms of β-lactam Resistance Among Pseudomonas aeruginosa
- (2012) Daniel J. Wolter et al. CURRENT PHARMACEUTICAL DESIGN
- Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010
- (2012) Dawn M. Sievert et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Pneumonia Due to Pseudomonas aeruginosa
- (2011) Hsin-Yun Sun et al. CHEST
- PcrV antibody–antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice
- (2011) Y. Song et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Recent developments for Pseudomonas vaccines
- (2011) Anurag Sharma et al. Human vaccines & immunotherapeutics
- Efficacy of a Conjugate Vaccine Containing Polymannuronic Acid and Flagellin against Experimental Pseudomonas aeruginosa Lung Infection in Mice
- (2011) Victoria L. Campodónico et al. INFECTION AND IMMUNITY
- Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of Yersinia pestis coupled to palmitate in mice
- (2011) SriJayaprakash Babu Uppada et al. VACCINE
- Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV – Implications for anti-PcrV immunotherapy
- (2010) Susan V. Lynch et al. MICROBIAL PATHOGENESIS
- Pseudomonas aeruginosa virulence and therapy: Evolving translational strategies*
- (2009) Jeffrey L. Veesenmeyer et al. CRITICAL CARE MEDICINE
- Population-Based Study of the Epidemiology and the Risk Factors for Pseudomonas aeruginosa Bloodstream Infection
- (2009) M. D. Parkins et al. INFECTION
- International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
- (2009) Jean-Louis Vincent JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Protective effects of affinity-purified antibody and truncated vaccines againstPseudomonas aeruginosaV-antigen in neutropenic mice
- (2009) Kiyoshi Moriyama et al. MICROBIOLOGY AND IMMUNOLOGY
- Alum adjuvanticity: Unraveling a century old mystery
- (2008) Ennio De Gregorio et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- An Engineered Human Antibody Fab Fragment Specific for Pseudomonas aeruginosa PcrV Antigen Has Potent Antibacterial Activity
- (2008) M. Baer et al. INFECTION AND IMMUNITY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started